Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Part of paid clinical trials in Stanford, California.

Sponsor
Shaheen Shagufta
Study ID
NCT01525082
Phase
PHASE2
Status
Completed

Conditions

  • Gastrinoma
  • Glucagonoma
  • Insulinoma
  • Pancreatic Polypeptide Tumor
  • Recurrent Islet Cell Carcinoma
  • Recurrent Pancreatic Cancer
  • Somatostatinoma
  • Stage III Pancreatic Cancer
  • Stage IV Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    Capecitabine by mouth twice daily on Days 1 to 14
  • Temozolomide — DRUG
    Temozolomide by mouth daily on Days 10 to 14
  • Bevacizumab — BIOLOGICAL
    Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15

Study Details

The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.

Key Dates

First listed
Feb 2, 2012
Start date
Dec 31, 2012
Status verified
Jan 2024
Primary completion
Jan 31, 2018
Completion
Dec 31, 2019

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + Capecitabine + Temozolomide
    Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.

Primary Outcome Measure

Radiographic Response (RR) [ Time Frame: 18 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University Medical CenterStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University Medical Center· Stanford, CA

Related Studies